<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887988</url>
  </required_header>
  <id_info>
    <org_study_id>OFx Registry_RP_v.1.0</org_study_id>
    <nct_id>NCT03887988</nct_id>
  </id_info>
  <brief_title>Orbital Fractures Registry</brief_title>
  <acronym>OFx</acronym>
  <official_title>International, Multicenter, Prospective Registry to Collect Data on Orbital Fractures (OFx), Their Primary and Secondary Treatment and Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO Clinical Investigation and Publishing Documentation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO Innovation Translation Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 300 patients presenting orbital blow-out fracture will be enrolled
      prospectively in this registry. All patients, surgically and nonsurgically treated as per
      standard (routine) of care will be followed-up (FU) within the registry for a period of 6
      months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 300 patients presenting with a displaced orbital fracture (OFx) in the floor
      and/or medial wall (blow-out fracture) will be enrolled prospectively in this registry. All
      patients, surgically and nonsurgical treated will be followed-up (FU) within the registry. FU
      period for all patients will include assessments post-treatment at 6 weeks, 3 months and 6
      months as corresponding with the local standard (routine) visit schedule at each
      participating clinic.

      Data collection includes patient and fracture details, treatment details, functional,
      clinical and patient-reported outcomes and anticipated or procedure- and implant-related
      adverse events (ie, complications). Computer Tomography (CT) scans or Cone Beam-CT (CBCT)
      scans taken as per standard of care will be collected within the registry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Diplopia</measure>
    <time_frame>24 weeks post-treatment</time_frame>
    <description>The degree of diplopia is quantified by measuring the field of single binocular vision, ranging from 0 to 3.
0: no diplopia
mild (diplopia appears more than 30 degrees from the primary position)
moderate (diplopia appears between 10 and 30 degrees from the primary position)
severe (diplopia appears within 10 degrees from the primary position)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Globe position</measure>
    <time_frame>6, 12, 24 weeks post-treatment</time_frame>
    <description>Exo/enophthalmos (in mm) using Naugle or Hertel exophthalmometer Hyper/hypophthalmos: vertical globe displacement is measured as the pupilar height difference (in mm) from the healthy side to the injured side</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6, 12, 24 weeks post-treatment</time_frame>
    <description>Measured using a visual test chart in healthy and injured sides with and without vision aids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-ocular mobility</measure>
    <time_frame>6, 12, 24 weeks post-treatment</time_frame>
    <description>Follow-my finger test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>pre-treatment, 6, 12, 24 weeks post-treatment</time_frame>
    <description>AOCMF Injury symptom battery Self-reported diplopia Self-perception of visual acuity, strabismus and symmetry</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Orbital Fractures</condition>
  <condition>Blow Out Fracture of Orbit</condition>
  <arm_group>
    <arm_group_label>Orbital Fracture</arm_group_label>
    <description>Patients with dislocated fracture of the inferior and/or medial orbital wall</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary &quot;early&quot; reconstruction</intervention_name>
    <description>Primary surgical reconstruction of the fracture within 3 weeks after injury</description>
    <arm_group_label>Orbital Fracture</arm_group_label>
    <other_name>Operative</other_name>
    <other_name>Surgical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nonsurgical</intervention_name>
    <description>Nonsurgical treatment of fracture</description>
    <arm_group_label>Orbital Fracture</arm_group_label>
    <other_name>Conservative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary &quot;delayed&quot; reconstruction</intervention_name>
    <description>Primary surgical reconstruction of the fracture more than 3 weeks after injury</description>
    <arm_group_label>Orbital Fracture</arm_group_label>
    <other_name>Operative</other_name>
    <other_name>Surgical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Secondary reconstruction</intervention_name>
    <description>Second surgical reconstruction of the fracture after a primary reconstruction.</description>
    <arm_group_label>Orbital Fracture</arm_group_label>
    <other_name>Secondary surgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years old with displaced fracture of the inferior and/or medial
        orbital wall (blow-out fractures) that require treatment (either surgically or
        non-surgically)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older at the time of the injury

          -  Patients with a dislocated fracture of the inferior and/or medial orbital wall, either

               -  Diagnosed at the study site via CT or CBCT within 2 weeks of the date of the
                  injury, OR

               -  Who will undergo secondary reconstruction

        Exclusion Criteria:

          -  Bilateral orbital fracture

          -  Concomitant displaced fracture(s) of the orbital roof or any other area of the orbit

          -  Concomitant ruptured globe

          -  Displaced fracture of the malar bone

          -  Displaced midface fracture

          -  Displaced nasoorbitoethmoidal (NOE) fracture or complex zygoma fractures

          -  Presence at the time of enrollment of any disease with influence on eye motility (eg,
             strabismus, myasthenia gravis, Graves' ophthalmopathy)

          -  Previous radiotherapy in the orbital region

          -  Participation in any other medical device or medicinal product study within the
             previous month(s) that could influence the results of the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eppo B. Wolvius, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oral &amp; Maxillofacial Surgery, Erasmus MC, Rotterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Diaz, PhD</last_name>
    <phone>+41 81 414 25 07</phone>
    <email>victor.diaz@aofoundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigitte Gallo, PhD</last_name>
    <phone>+41 44 200 24 06</phone>
    <email>brigitte.gallo@aofoundation.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Strong, MD</last_name>
      <phone>916-734-5573</phone>
      <email>ebstrong@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashkan Rashad, MD</last_name>
      <email>a.rashad@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenko Smolka, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eramus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eppo Wolvius</last_name>
      <email>e.wolvius@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Hospital</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nabeela Riaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moustafa Alkhalil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital of Constanta</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Vlad, MD</last_name>
      <email>dan_vlad@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Edward VIII Hospital</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivesh Rughubar, MD</last_name>
      <email>viveshr@netactive.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jogre Masià, MD</last_name>
      <email>jorgemasiag@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>12 de Octubre University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Rivero Calle, MD</last_name>
      <email>alvaro.rivero@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Thor, MD</last_name>
      <email>andreas.thor@akademiska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Thieringer, MD</last_name>
      <email>Florian.Thieringer@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Pakistan</country>
    <country>Qatar</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fracture fixation</keyword>
  <keyword>Orbital implant</keyword>
  <keyword>Midface fracture</keyword>
  <keyword>Diplopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orbital Fractures</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

